Technology
Health
Biotechnology

AnaptysBio

$71.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$4.22 (-5.60%) Today
+$0.21 (0.30%) After Hours

Why Robinhood?

You can buy or sell AnaptysBio and other stocks, options, ETFs, and crypto commission-free!

About

AnaptysBio, Inc. Common Stock, also called AnaptysBio, is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Read More Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Employees
78
Headquarters
San Diego, California
Founded
2005
Market Cap
1.92B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
360.65K
High Today
$75.17
Low Today
$70.92
Open Price
$75.00
Volume
76.86K
52 Week High
$122.48
52 Week Low
$54.26

Collections

Technology
Health
Biotechnology
Medical
2017 IPO
US
North America

News

Simply Wall StMar 12

Did You Manage To Avoid AnaptysBio’s (NASDAQ:ANAB) 42% Share Price Drop?

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. Investors in AnaptysBio, Inc. (NASDAQ:ANAB) have tasted that bitter downside in the last year, as the share price dropped 42%. That’s well bellow the market return of 1.4%. AnaptysBio hasn’t been listed for long, so although we’re wary of recent listings that perform poorly, it may still prove itself with ...

230
MarketBeatMar 11

Stock Price, News, & Analysis for AnaptysBio

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular p...

9
Yahoo FinanceMar 6

All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy

AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy). AnaptysBio, Inc. (ANAB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Conse...

66

Earnings

-$0.92
-$0.62
-$0.31
-$0.01
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.